A structured step toward modernizing preclinical drug development

The U.S. Food and Drug Administration’s release of the draft guidance, General Considerations for the Use of New Approach Methodologies in Drug Development, marks an important milestone in the evolution of preclinical science.

More than a general statement of support for New Approach Methodologies (NAMs), the document provides a practical validation framework for how these methods may be considered in drug development and regulatory submissions.

This matters because the field has now moved beyond broad discussion of whether NAMs should play a larger role in drug development. The more immediate question is how they should be evaluated, where they can add value, and what level of confidence is needed for regulatory decision-making.

In that respect, the new draft guidance is significant. It does not attempt to endorse individual platforms or prescribe a single pathway for adoption. Instead, it lays out the core scientific principles the FDA expects developers to address when using NAMs to support nonclinical programs.

Taken together with the FDA’s April 2025 Roadmap to Reducing Animal Testing in Preclinical Safety Studies and the December 2025 draft guidance on streamlined nonclinical safety studies for certain monoclonal antibodies, this new document signals continued progression in the agency’s effort to modernize preclinical development workflows.

From regulatory momentum to usable framework

Over the past several years, regulatory and policy signals around NAMs have become increasingly clear. Legislative changes in 2022 clarified that non-animal data may be sufficient to support an IND or biosimilar BLA in appropriate cases. The FDA’s 2025 roadmap then outlined a broader strategy for reducing animal testing through scientifically validated human-relevant methods.

The monoclonal antibody draft guidance that followed in late 2025 demonstrated that the agency was willing to discuss streamlined nonclinical approaches in a defined product class.

The newly released NAMs draft guidance builds on that progression. Its importance lies in the fact that it provides not simply encouragement, but structure. It gives sponsors a framework for thinking about validation in a regulatory context and reinforces that NAMs are no longer peripheral tools reserved for exploratory work. They are increasingly part of the mainstream nonclinical discussion, provided they are used in a scientifically justified manner.

The FDA’s accompanying announcement underscores this point, describing the guidance as another major milestone in implementing the agency’s roadmap and in moving away from animal testing as the default method for generating drug safety information.

What the guidance does, and does not, attempt to do

One of the strengths of the document is that it is appropriately scoped. The guidance does not attempt to catalog specific technologies, nor does it address NAM use in drug discovery. Rather, it focuses on general validation considerations when NAM data are submitted in support of drug development decisions. This is an important distinction.

The document is less about promoting one model over another and more about defining the scientific standards that make any model interpretable and useful in a regulatory setting.

The guidance also makes clear that it is nonbinding and recommendation-based. That is consistent with FDA guidance practice, but it should not be mistaken for lack of importance. In practical terms, documents such as this shape expectations across industry, inform internal development planning, and signal where review divisions are increasingly prepared to engage.

Here, the agency is clearly communicating that NAM-supported packages will be evaluated through a structured lens centered on scientific rigor, relevance, and decision utility.

The four pillars of FDA’s validation framework

At the center of the draft guidance are four core validation considerations: context of use, human biological relevance, technical characterization, and fit-for-purpose. These concepts are familiar to many working in the NAMs space, but their consolidation into a single FDA framework is meaningful because it reinforces what regulators view as the essential elements of confidence.

Context of use

The guidance places appropriate emphasis on context of use (COU) as the starting point for any regulatory discussion. The FDA describes COU as the intended use and regulatory purpose of the NAM in a specific drug development decision context. In other words, a model cannot be assessed in the abstract. Its value depends on the question it is being used to answer.

A NAM may be useful for dose selection, mechanistic interpretation of an adverse event, supporting the extent of clinical monitoring, justifying why a particular animal species adds little value, or contributing to a broader weight-of-evidence assessment.

This is one of the most important features of the guidance. It reinforces that regulatory utility is not determined by technological sophistication alone. A highly complex system with poorly defined purpose may be less useful than a simpler assay that is tightly aligned to a specific decision. For a field that has sometimes focused heavily on platform complexity, the FDA’s framing is a useful reminder that decision relevance must remain central.

Human biological relevance

The second pillar is human biological relevance. Here, the agency asks sponsors to demonstrate how the NAM reflects the human biology needed to inform the intended question. This includes describing the physiological features being assessed, the relevance of the cell types used, the species of origin, the anatomical and functional characteristics represented in the system, and how the measured endpoints relate to human outcomes.

The guidance provides examples across neurotoxicity, hepatotoxicity, respiratory toxicity, and developmental toxicity to illustrate that biological relevance must be established through more than general claims of “human-derived” status.

This part of the guidance is especially important because it pushes the field beyond a simplistic alternative-versus-traditional framing. A NAM is not useful merely because it is non-animal or more novel. It must capture the biology necessary to answer the relevant question. That expectation is scientifically sound and highly aligned with the broader push toward fit-for-purpose model selection.

Technical characterization

The third pillar, technical characterization, addresses the need for scientific confidence in how the method performs. The FDA emphasizes assay robustness, reliability, reproducibility, endpoint definition, statistical analysis, assay duration, control selection, cell source documentation, donor and biological variability, and other practical factors that influence interpretability.

The guidance also calls attention to issues especially relevant for more complex platforms such as organ chips, including flow conditions, matrix properties, scaffold characteristics, absorption of test articles, material leaching, and biomaterial compatibility.

This is a critical section because it makes clear that the burden on NAMs is not simply to be innovative, but to be technically defensible. In many ways, this is where enthusiasm for emerging systems must meet the realities of regulatory science. Reproducibility, transparency, and control of variability remain essential. The guidance therefore reinforces that successful adoption will depend not only on biological promise, but on disciplined method development and reporting.

Fit-for-purpose

The fourth pillar, fit-for-purpose, brings the earlier concepts together. The FDA states that a NAM is fit-for-purpose if it assists CDER in regulatory decision-making. The document identifies three broad roles a NAM may serve: replacing or offering an alternative to traditional methods, filling a data gap where traditional models are unavailable or inadequate, or confirming and complementing findings from traditional studies. It also recommends comparing NAM performance to traditional methods when such comparators exist and discussing both strengths and limitations of the approach.

This framing is particularly useful because it acknowledges that regulatory value can come from different forms of contribution. Not every NAM must fully replace an animal study to be meaningful. In many cases, the most immediate value may lie in clarifying mechanism, refining species selection, improving interpretation of risk, or providing more human-relevant information where traditional models are weak.

A particularly important signal: validation is not binary

One of the most consequential points in the guidance is the FDA’s statement that, for a NAM to be considered in drug development review, the test does not necessarily need to be formally validated. The agency notes that a fit-for-purpose NAM, even if not fully validated, may adequately address specific toxicological concerns when used in the context of the overall weight of evidence.

This is an important and pragmatic position. It avoids imposing an unrealistic all-or-nothing threshold while still maintaining scientific expectations. It also reflects how drug development decisions are actually made: rarely on the basis of a single study in isolation, but rather through integration of prior knowledge, mechanistic understanding, product-specific concerns, and multiple lines of evidence.

By explicitly emphasizing weight of evidence and fit-for-purpose use, the guidance supports a more flexible but still rigorous pathway for regulatory incorporation of NAMs.

For the field, this may be one of the most valuable aspects of the document. It shifts the discussion away from a narrow binary of ‘validated’ versus ‘not validated’ and toward a more scientifically relevant question: whether the method is appropriate, reliable, and informative for the decision at hand.

Broader context: this is part of a larger shift

Although the new draft guidance should stand on its own merits, it also sits within a much broader movement. The FDA’s March 18 announcement explicitly positioned the document as part of the agency’s ongoing implementation of its roadmap to reduce animal testing. The NIH, on the same day, announced more than $150 million in support of human-based research methods through its Complement-ARIE program, including infrastructure for validation, qualification, standards development, and public-private implementation efforts.

The UK, in late 2025, likewise published a national strategy focused on development, validation, uptake, and regulatory confidence in alternative methods, emphasizing that the right question is not whether an alternative reproduces animal data perfectly, but whether it provides the information needed to make the appropriate scientific or regulatory decision.

That broader context matters because it suggests this is not an isolated FDA action. Rather, it is part of an increasingly coordinated shift across regulators, funders, and policy makers toward more human-centric development paradigms. The scientific, regulatory, and infrastructure pieces are beginning to align.

Implications for the drug development community

For sponsors, the immediate implication is that NAMs should increasingly be considered as part of program strategy rather than as ancillary exploratory tools. The guidance strongly suggests that successful use will require early definition of context of use, careful attention to biological relevance and technical performance, and proactive engagement with review divisions when questions exist about suitability.

For model developers, the guidance reinforces that platform novelty alone will not drive adoption. Regulatory uptake will depend on clear positioning within a decision context, robust characterization, transparent performance data, and realistic articulation of limitations. The field is moving toward evidence-backed deployment, not technology-first enthusiasm.

For the broader ecosystem, including CROs, translational partners, data groups, and providers of human-derived materials, the document points to growing demand for standardized inputs, well-characterized biological systems, and collaborative validation efforts. As the regulatory conversation becomes more structured, the supporting infrastructure around NAMs will matter even more.

Conclusion

The FDA’s latest draft guidance is important not because it declares the end of animal testing, but because it provides a credible and workable framework for moving beyond animal testing where scientifically justified.

It recognizes both the promise and the practical challenges of NAMs. It avoids overstating what current methods can do yet clearly signals that the agency expects the field to advance through rigor, relevance, and fit-for-purpose application.

Perhaps most importantly, the guidance reflects a maturing regulatory perspective. The question is no longer whether NAMs belong in drug development. They already do. The question is how they should be defined, characterized, and applied so that they improve decision-making and strengthen confidence in human risk assessment.

In that sense, this document represents more than another policy milestone. It is part of the practical architecture for a more modern preclinical paradigm, one built not on default reliance on historical convention, but on the disciplined use of tools that are most informative for the question being asked.

BioIVT support for NAMs implementation

As a global supplier of biospecimens and contract research services, BioIVT has been assisting organizations with the implementation of NAMs in their research and development programs. This assistance ranges from extensive informational resources like this article to products and services, such as consulting services for strategic planning and gap analysis; high quality, extensively characterized cells, tissue and other biospecimen preparations for NAM starting materials; and ADME-Tox services utilizing the company’s own NAM test systems.

As Consulting Director on BioIVT’s Scientific Affairs team, Dr. Kent Grindstaff assists clients with their development programs, leveraging real-world experience to provide tailored solutions that address their research needs and regulatory compliance.